UnitedHealthcare denied your biologic and infusion therapy? Here is what to do next

Why UnitedHealthcare denies biologic and infusion therapy

UnitedHealthcare is the largest U.S. health insurer by membership and runs commercial, Medicare Advantage, and Medicaid plans. Denial volume is correspondingly high, but so is the reversal rate when appeals are filed correctly.

For biologic and infusion therapy specifically: Biologics such as adalimumab, infliximab, vedolizumab, ustekinumab, and rituximab are denied at prior authorization for step-therapy, missing labs, or diagnosis mismatch, and later for site of care or dose escalation. The appeal is a documentation exercise against the plan's own criteria.

What UnitedHealthcare denies for biologic and infusion therapy

The biologic and infusion therapy services most often denied:

• First biologic for Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, or psoriasis
• Switch to a second biologic after the first stops working
• Dose escalation or interval shortening beyond the label
• Infusion at a hospital outpatient department instead of home or a standalone center
• Biosimilar substitution disputes

Why biologic and infusion therapy claims get denied

A typical UnitedHealthcare biologic and infusion therapy denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

• Step therapy: conventional drugs (methotrexate, mesalamine, steroids) not tried or not documented
• Disease activity scores or lab markers missing from the record
• Diagnosis code does not match the labeled indication
• TB or hepatitis B screening not on file
• Plan prefers a different biologic or a biosimilar first

The UnitedHealthcare appeal process

Appeal levels: Internal level 1 (30 days for standard, 72h expedited), internal level 2 (in some states), then external/independent review. Medicare Advantage adds federal levels 2-5 (IRE → ALJ → Council → District Court).

Carrier timing: Standard appeals must be filed within 180 days of the denial date. Urgent designations compress carrier response time to 72 hours. Medicare Advantage level-2 deadline is 60 days from level-1 denial.

Biologics timing: Untreated inflammatory disease supports an expedited appeal: decision within 72 hours. Internal appeal filing window: at least 180 days for commercial and employer plans; 65 days for Medicare Advantage; 60 days for Part D. External review: within 4 months of the final internal denial for ACA-covered plans (45 CFR 147.136).

What we know about UnitedHealthcare: We file all UHC appeals with the criteria-disclosure request embedded in the cover letter. This anchors the procedural record from day one.

Common UnitedHealthcare denial patterns for biologic and infusion therapy

• Clinical criteria withheld in initial denial. UHC denials frequently cite 'not medically necessary' without disclosing the specific clinical criteria applied. Federal and state law require disclosure on request, and once disclosed, the criteria become the rebuttal map.
• Specialty-drug formulary denials. Specialty injectables are often denied at the pharmacy benefit (Optum Rx) before they reach the medical benefit. Filing a formulary exception with manufacturer clinical data is the standard reversal path.
• Medicare Advantage prior auth. UHC's Medicare Advantage plans have been the subject of multiple federal investigations into prior-auth denial rates. A substantial share of these denials reverse at level 1 once the appeal supplies the withheld clinical criteria; level 2 (IRE/Maximus) is where escalation cases tend to land.

How to win your UnitedHealthcare biologic and infusion therapy appeal

Strategy for biologic and infusion therapy: Get the plan's drug policy and match every criterion to a page in the chart: diagnosis, severity score, prior drugs with dates and outcomes, screening labs, prescriber specialty. Where step therapy is the reason, use the plan's exception process and, where applicable, the state step-therapy law that requires an override when the required drug was tried, is contraindicated, or is expected to be ineffective. For a switch after loss of response, document the objective loss of response. Ask for a peer-to-peer with a reviewer in the same specialty.

Filed against UnitedHealthcare, that strategy rides on this procedural spine:

1. Procedural-rights anchor. Every UnitedHealthcare denial triggers ERISA § 503 or 45 C.F.R. § 147.136 procedural rights. The cover letter invokes these in the opening paragraph to lock the timeline and force criteria disclosure.
2. Criteria-disclosure demand. UnitedHealthcare frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
3. Controlling-standard citation. Plan drug policies typically require a specific diagnosis, disease severity measures, a trial of conventional therapy (step therapy), tuberculosis and hepatitis screening, and prescriber specialty. Many states limit step therapy and require exception processes; federal rules for ACA plans require an exceptions process for non-formulary drugs (45 CFR 156.122(c)). Medicare Part B covers physician-administered biologics under medical necessity; Part D covers self-administered ones under formulary rules with a 60-day redetermination window (42 CFR 423.582). Criteria must be disclosed on request (29 CFR 2560.503-1(m)(8)).
4. Treating-provider attestation. A letter from the treating physician addressing each criterion in UnitedHealthcare's own policy language. This is the single strongest evidentiary element.
5. Requested action. A specific demand to reverse the biologic and infusion therapy denial and approve the service, not a general "please reconsider."

Documents you'll need for your UnitedHealthcare biologic and infusion therapy appeal

• The denial letter with the criterion or policy cited
• Specialist's notes with diagnosis and disease-activity measures
• Prior medication history with dates, doses, and outcomes
• TB, hepatitis, and other screening results
• The plan's drug policy and formulary exception form

What a biologic and infusion therapy appeal can recover

Typical recovery for biologic and infusion therapy cases runs Biologics are priced in the thousands of dollars per dose; a denied year of therapy is commonly a five-figure sum at billed charges.. The exact figure depends on the specific service and your plan's contracted rates.

UnitedHealthcare biologic and infusion therapy appeals: frequently asked questions

What Apellica does for UnitedHealthcare biologic and infusion therapy appeals

We file appeals against UnitedHealthcare specifically configured to its internal review process. Every biologic and infusion therapy appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for UnitedHealthcare appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Related UnitedHealthcare guides

• UnitedHealthcare surgery denials appeal guide
• UnitedHealthcare mri and imaging denials appeal guide
• UnitedHealthcare medication and prescription denials appeal guide
• UnitedHealthcare medicare denials appeal guide

Biologic and infusion therapy guides for other carriers

• Aetna (CVS Health) biologic and infusion therapy appeal guide
• Cigna (Evernorth) biologic and infusion therapy appeal guide
• Anthem / BlueCross BlueShield biologic and infusion therapy appeal guide
• Humana biologic and infusion therapy appeal guide